BioLargo (BLGO) 10-Q 14 Aug 17 2017 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 11, 2017
Document Information [Line Items]
Entity Registrant Name	BIOLARGO, INC.
Entity Central Index Key	880,242
Trading Symbol	blgo
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		100,585,385
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 433,539	$ 1,910,153
Accounts receivable	78,105	67,994
Inventories	36,907	34,446
Prepaid expenses and other current assets	12,795	4,089
Total current assets	561,346	2,016,682
Equipment, net of depreciation	50,336	59,315
Other non-current assets, net of amortization	31,269	36,729
Total assets	642,951	2,112,726
Current liabilities:
Accounts payable and accrued expenses	344,438	200,103
Accrued officer bonus		80,000
Convertible notes payable	4,830,097	560,000
Discount on convertible notes payable and line of credit, net of amortization	(2,108,435)	(398,910)
Derivative warrant liability	570,595	663,560
Line of credit	50,000	50,000
Deposit	50,000
Total current liabilities	3,736,695	1,154,753
Long-term liabilities:
Convertible notes payable	675,571	5,250,668
Line of credit	250,000
Discount on convertible notes payable and line of credit, net of amortization	(543,483)	(3,522,497)
Total liabilities	4,118,783	2,882,924
COMMITMENTS, CONTINGENCIES (Notes 8 and 9)
STOCKHOLDERS’ DEFICIT:
Convertible Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2016 and June 30, 2017.
Common stock, $.00067 Par Value, 200,000,000 Shares Authorized, 92,975,970 and 99,898,718 Shares Issued, at December 31, 2016 and June 30, 2017, respectively.	66,885	62,179
Additional paid-in capital	92,533,290	90,609,774
Accumulated deficit	(96,256,129)	(91,915,426)
Accumulated other comprehensive loss	(97,680)	(81,694)
Total Biolargo stockholders’ deficit	(3,753,634)	(1,325,167)
Non-controlling interest (Note 6)	277,802	554,969
Total stockholders’ deficit	(3,475,832)	(770,198)
Total liabilities and stockholders’ deficit	$ 642,951	$ 2,112,726

Consolidated Balance Sheets (C3

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.00067	$ 0.00067
Convertible Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued (in shares)	0	0
Convertible Preferred Stock, Shares Outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.00067	$ 0.00067
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	99,898,718	92,975,970

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenues	$ 99,978	$ 38,986	$ 145,995	$ 52,928
Cost of revenues	(73,399)	(15,757)	(95,929)	(21,838)
Gross profit:	26,579	23,229	50,066	31,090
Selling, general and administrative expenses	1,162,018	923,564	2,217,073	1,854,471
Research and development	324,280	329,968	715,616	681,018
Amortization and depreciation	6,515	2,845	14,439	5,575
Total operating expenses:	1,492,813	1,256,377	2,947,128	2,541,064
Operating loss:	(1,466,234)	(1,233,148)	(2,897,062)	(2,509,974)
Other (expense) income:
Interest expense	(1,119,273)	(478,525)	(2,072,829)	(884,850)
Change in fair value of derivative warrant liability	56,352		321,872
Grant income	11,361	43,338	70,149	82,096
Total other expense:	(1,051,560)	(435,187)	(1,680,808)	(802,754)
Net loss	(2,517,794)	(1,668,335)	(4,577,870)	(3,312,728)
Net loss attributable to noncontrolling interest	(173,911)	(54,859)	(237,167)	(121,831)
Net loss attributable to common shareholders	$ (2,343,883)	$ (1,613,476)	$ (4,340,703)	$ (3,190,897)
Net loss per share attributable to common shareholders:
Loss per share attributable to shareholders – basic and diluted (in dollars per share)	$ (0.03)	$ (0.02)	$ (0.05)	$ (0.04)
Weighted average number of common shares outstanding: (in shares)	97,770,161	86,419,573	94,718,273	86,133,395
Comprehensive loss:
Net loss	$ (2,517,794)	$ (1,668,335)	$ (4,577,870)	$ (3,312,728)
Foreign currency translation	32,150	(606)	(15,986)	(9,924)
Comprehensive loss	(2,485,644)	(1,668,941)	(4,593,856)	(3,322,652)
Comprehensive loss attributable to noncontrolling interest	(173,911)	(54,859)	(237,167)	(121,831)
Comprehensive loss attributable to common stockholders	$ (2,311,733)	$ (1,614,082)	$ (4,356,689)	$ (3,200,821)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - 6 months ended Jun. 30, 2017 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2016	92,975,970
Balance at Dec. 31, 2016	$ 62,179	$ 90,609,774	$ (91,915,426)	$ (81,694)	$ 554,969	$ (770,198)
Vendors and interest (in shares)	2,491,704
Vendors and interest	$ 1,734	502,259				504,263
Conversion of notes (in shares)	1,419,107
Conversion of notes	$ 952	529,048				$ 530,000
Exercise of warrants (in shares)	510,000					510,000
Exercise of warrants	$ 343	152,657				$ 153,000
Exercise of stock options (in shares)	2,501,937
Exercise of stock options	$ 1,677	(1,677)
Stock option compensation expense		515,959				515,959
Fair value of warrants and conversion feature issued as discount on convertible notes payable		225,000				225,000
Purchase of Clyra shares					(40,000)	(40,000)
Net loss			(4,340,703)		(237,167)	(4,577,870)
Foreign currency translation				(15,986)		(15,986)
Balance (in shares) at Jun. 30, 2017	99,898,718
Balance at Jun. 30, 2017	$ 66,885	$ 92,533,290	$ (96,256,129)	$ (97,680)	$ 277,802	$ (3,475,832)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Net loss	$ (4,577,870)	$ (3,312,728)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	515,959	491,440
Common stock issued for interest and in lieu of salary to officers and fees for services from consultants	504,263	489,107
Interest expense related to amortization of the discount on convertible notes payable and line of credit and deferred financing costs	1,723,396	668,257
Change in derivative liability	(321,872)
Amortization and depreciation expense	14,439	5,575
Bad debt expense	15,000
Changes in assets and liabilities:
Accounts receivable	(25,111)	(5,275)
Inventories	(2,461)	13,555
Prepaid expenses and other current assets	(8,706)	5,247
Accounts payable and accrued expenses	144,335	(13,839)
Officer bonus	(80,000)
Deposits	50,000	(35,000)
Net cash used in operating activities	(2,048,628)	(1,693,661)
Cash flows from investing activities
Equipment purchase		(5,500)
Net cash used in investing activities		(5,500)
Cash flows from financing activities
Proceeds from convertible notes	225,000	535,000
Proceeds from line of credit	250,000	300,000
Purchase of Clyra Shares	(40,000)
Proceeds from exercise of warrants	153,000
Net cash provided by financing activities	588,000	835,000
Effect of foreign currency translation	(15,986)	(9,924)
Net change in cash and cash equivalents	(1,476,614)	(874,085)
Cash and cash equivalents at beginning of period	1,910,153	1,763,114
Cash and equivalents at end of period	433,539	889,029
Supplemental disclosures of cash flow information
Interest	4,487
Income taxes	5,350	4,000
Non-cash investing and financing activities
Conversion of accounts payable into stock options	243,824	183,159
Fair value of warrants issued in conjunction with convertible notes payable	225,000	772,405
Settlement of accounts payable and interest into shares of common stock	504,263	489,107
Convertible notes into shares of common stock	$ 530,000

Note 1 - Business and Organizat

Note 1 - Business and Organization	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Outlook The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. As reflected in the accompanying financial statements, for the six June 30, 2017 $4,577,870, $2,048,628 June 30, 2017, $3,175,349, $561,346, $96,256,129. not We have been, and anticipate that we will continue to be, limited in terms of our capital resources. Our total cash balance was $433,539 June 30, 2017. $1,400,000 December 31, 2016 June 30, 2017. six June 30, 2017 three 2016, not not third 12 June 30, 2017, $800,000 9. As of June 30, 2017, $5,805,668 3 4,830,097 June 30, 2017, $344,438 6 The unaudited consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8 03 X 1933, not six June 30, 2017 not may December 31, 2017, Form 10 December 31, 2016 March 30, 2017. We operate six 2006, No 2009, 2013, 2014, 2016, 2016. 2012.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based compensation and financing transactions, uncollectible accounts receivable, asset impairment and amortization, and taxes, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. Share-based Payments All share-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values. For stock issued to consultants and other non-employees for services, we record the expense based on the fair market value of the securities as of the date of the stock issuance. The issuance of fully vested stock warrants or options to non-employees are valued at the time of issuance utilizing the Black Scholes calculation and the amount is charged to expense. The issuance of stock warrants or options to non-employees that vest over time are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the warrants or options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting. Warrants The Unit Offerings of our convertible promissory note and a Series A stock purchase warrant are accounted for under the fair value and relative fair value method. The warrant is first not. If the warrant is determined to not The convertible note is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) which the effective convertible price of the note is less than the closing stock price on date of issuance. The adjusted BCF value is accounted for as equity. The warrant and BCF fair values are also recorded as a discount to the convertible promissory notes. The equity features of the convertible promissory notes resulted in a discount to the convertible notes that is equal to the proceeds received. Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. Foreign Currency The Company has designated the functional currency of Biolargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income. Revenue Recognition Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. We also may one Government Grants We have been awarded grants from the Canadian National Research Institute – Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC). The government grants received are considered other income and are included in our consolidated statements of operations. We received our first 2015 thirty $1,100,000. third six eighteen not The grants provide for (i) recurring monthly amounts and (ii) reimbursement of costs for research talent for which we invoice to request payment and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three six June 30, 2016 2017, Concentrations of Credit Risk All highly liquid investments with original maturities of three one June 30, 2017 December 31, 2016, $250,000 not June 30, 2017 December 31, 2016, $183,539 $1,660,153, Allowance for uncollectible receivables Management evaluates credit quality by evaluating the exposure to individual counterparties, and, where warranted, management also considers the credit rating or financial position, operating results and/or payment history of the counterparty. Management establishes an allowance for amounts for which collection is considered doubtful. Adjustments to previous assessments are recognized in income in the period in which they are determined. At June 30, 2017, $15,000. Recent Accounting Pronouncements In April 2016, 2016 10, 606 2014 09, 606 December 15, 2017. not In March 2016, No. 2016 09, two December 15, 2017. In February 2016, No. 2016 02, 12 December 15, 2018, not

Note 3 - Convertible Notes Paya

Note 3 - Convertible Notes Payable and Lines of Credit	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 3. DECEMBER 31, 201 6 JUNE 3 0 , 201 7 Current liabilities: Line of credit, matures December 1, 2017 $ 50,000 $ 50,000 Convertible notes payable One-Year Convertible notes, mature July 8, 2017 $ 280,000 $ — One-Year Convertible notes, mature December 30, 2017 280,000 280,000 Convertible notes, mature June 1, 2018* — 4,550,097 Total convertible notes payable $ 560,000 $ 4,830,097 Long-term liabilities: Clyra Line of credit, matures March 31, 2019 $ — $ 250,000 Convertible notes payable, net of current portion Convertible notes, mature June 1, 2018* $ 4,800,097 $ — Convertible notes, mature September 17, 2019 283,571 283,571 Convertible notes, mature December 31, 2019 167,000 292,000 Convertible notes, mature June 20, 2020 — 100,000 Total convertible notes payable , net of current portion $ 5,250,668 $ 675,571 Total $ 5,860,668 $ 5,805,668 * The convertible notes that mature June 1, 2018, December 31, 2016, one June 30, 2017. For the three six June 30, 2016, $478,525 $884,850 three six June 30, 2017, $1,119,273 $2,072,829 Line of Credit, matures December 1, 2017 On June 6, 2016, $300,000 18% may nine December 1, 2017. Each investor, for no 5. one On September 17, 2016, $250,000 2015 As of December 31, 2016, June 30, 2017, $50,000 One-Year Convertible N otes, mature July 8, 2017 On July 8, 2016, $250,000 $0.45 July 8, 2017 two $280,000. 3% 400,000 $0.65 five 5. On January 13, 2017, $280,000 640,889 One-Year Convertible Note s , mature December 30, 2017 On December 30, 2016, $250,000 $0.57 December 30, 2017 two $280,000. 3% 400,000 $0.75 five 5. Subsequent to June 30, 2017, 9. Convertible Notes, mature June 1, 2018 ( 2015 On January 15, 2015, “2015 September 16, 2016. five June 1, 2018. Interest due may 20 may may ten three June 15, 2017, Each investor, for no 5 As of June 30, 2017, 2015 June 1, 2018 Unit/ Conversion Price Warrant Exercise Price Aggregate $ 0.25 $ 0.40 $ 1,652,384 $ 0.35 $ 0.45 1,751,046 $ 0.55 $ 0.70 1,146,667 $ 4,550,097 During the six June 30, 2017, $250,000 2015 406,789 During the six June 30, 2016, $535,000, June 1, 2018, 12% Clyra Line of Credit, matures March 31, 2019 On March 31, 2017, 54% $250,000 10% 5% may March 31, 2019. $175,000 three March 31, 2017. March 31, 2017, $75,000. June 30, 2017, 9 Convertible Notes, mature September 17, 2019 On September 17, 2016, December 1, 2017,” $250,000 $33,571 55 September 17, 2019, 2015 $0.70 September 17, 2016. 515,583 $0.70 5. Convertible Notes, mature December 31, 2019 ( 2016 On December 27, 2016, 2016 $600,000 $0.57 $0.86, December 31, 2019, 12% 20 may When paid in shares, the number of shares to be issued shall be calculated by dividing the principal amount invested by the $0.57 may ten three $0.57 one $0.70 December 31, 2021 ( 5 may 30 10 two 1 January 24, 2017. Subsequent to December 31, 2016, January 13, 2017, $125,000 three 219,298 $292,000 six $292,000, 512,281 Convertible Notes, mature June 20, 2020 ( 2017 On May 24, 2017, 2017 $1,500,000 $0.42 June 20, 2020, 12% 20 may When paid in shares, the number of shares to be issued shall be calculated by dividing the principal amount invested by the $0.42 may ten three $0.42 one $0.65 June 20, 2022 ( 5 may 30 10 two

Note 4 - Share-based Compensati

Note 4 - Share-based Compensation	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 4. Common Stock On May 2, 2017, 9, 1,500,000 $3,000,000 $3,000,000 12 Stock options During the three six June 30, 2016, $189,601 $491,440, three six June 30, 2017, $235,671 $515,959, 2007 2007 2007 On August 7, 2007, April 29, 2011, 2007 “2007 may may On June 19, 2017, 40,000 2007 $0.43 $15,600 On February 10, 2017, one 300,000 $0.69 February 10, 2027, 125,000 February 10, 2017, 25,000 March 1, 2017, $ 207,000 three six June 30, 2017, $51,750 $155,250 September 30, 2017. On June 20, 2016, 40,000 2007 $0.45 $18,000 On March 21, 2016, five 307,777 March 2011. March 21, 2021. $119,971 Activity for our stock options under the 2007 six June 30, 2016 2017 Weighted Balance, June 30, 2016: Average Options Shares Exercise Price per Outstanding Available Price per share share Balances as of December 31, 2015 10,241,086 1,758,914 $0.23 – 1.89 $ 0.44 Granted 40,000 (40,000 ) 0.45 0.45 Expired — — — — Balance, June 30, 2016 10,281,086 1,718,914 $0.23 – 1.89 $ 0.44 Weighted Average Balance, June 30, 2017: Options Shares Exercise Price per Outstanding Available Price per share share Balances as of December 31, 2016 9,916,586 1,981,414 $0.23 – 1.89 $ 0.44 Granted 340,000 (340,000 ) 0.39 – 0.69 0.65 Exercised — — — — Balance, June 30, 2017 10,256,586 1,641,414 $0.23 – 1.89 $ 0.44 Options issued Outside of the 2007 During the three six June 30, 2017, 237,353 820,879 $0.43 $0.67 three six June 30, 2017, $120,311 $277,074 On May 2, 2017, 3,731,322 $0.45 ten five not $1,679,095 May 2, 2022. three June 30, 2017, $27,985 During the three six June 30, 2016, 220,554 484,077 $0.33 $0.45 three six June 30, 2016, $96,196 $183,159 The fair value of the options issued prior to 2016 three six June 30, 2016, $75,405 $170,310, three six June 30, 2017, $20,025 $40,050. Exercise of Stock Option On April 30, 2017, 3,866,630 April 30, 2007. $0.18 2,501,937 $0.51 $0.18 No 3,866,629 Pursuant to a “lock-up agreement” dated April 30, 2017, $3,000,000 $3,000,000 12 May 2, 2017 Activity of our stock options issued outside of the 2007 six June 30, 2016 2017 Weighted Balance, June 30, 2016: Average Options Exercise Price per Outstanding Price per share share Balance, December 31, 2015 19,394,975 $0.18 – 1.00 $ 0.40 Granted 484,077 0.33 – 0.45 0.38 Exercised (60,000 ) 0.25 0.25 Balance, June 30, 2016 19,819,052 $0.18 – 1.00 $ 0.41 Weighted Average Balance, June 30, 2017: Options Exercise Price per Outstanding Price per share share Balance, December 31, 2016 20,148,766 $0.18 – 1.00 $ 0.43 Granted 4,552,201 0.43 – 0.67 $ 0.47 Expired (3,866,629 ) 0.18 0.18 Exercised (3,866,630 ) 0.18 0.18 Balance, June 30, 2017 16,967,708 $0.18 – 1.00 $ 0.41 We recognize employee compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. The following methodology and assumptions were used to calculate share based compensation for the six June 30: 2016 2017 Non Plan 2007 Plan Non Plan 2007 Plan Risk free interest rate 1.77 – 1.91% 1.26 – 1.36% 2.29 – 2.40% 2.31 – 2.40% Expected volatility 641 – 645% 311 – 315% 578 – 601% 578 – 601% Expected dividend yield — — — — Forfeiture rate — — — — Expected life in years 7 5 7 7 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Historically, we have not

Note 5 - Warrants

Note 5 - Warrants	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Warrants [Text Block]	Note 5. We recorded $668,257 $1,723,396 six June 30, 2016 2017, Warrants Issued Concurrently with the Summer 2017 Unit Offering During the three June 30, 2017, 2017 3 238,096 $0.65 June 20, 2022. $125,000 Warrants Issued Concurrently with the Winter 2016 During the three March 31, 2017, 2016 3 219,298 $0.70 December 31, 2021. $125,000 The Winter 2016 January 13, 2017, 512,281 $0.70 Warran ts Issued Concurrently with One- Year Convertible Notes On July 8, 2016, 400,000 $0.65 July 8, 2021. $160,000 one may 2015 May 24, 2017, 2017 $0.42 3 July 8, 2016 65 42 219,048 619,048 not On December 30, 2016 400,000 $0.75 December 30, 2021. $0.83. $280,000 one may 2015 May 24, 2017, 2017 $0.42 3 December 30, 2016 75 42 314,285 714,285 not The fair value of these warrants on June 30, 2017, $570,595 three six June 30, 2017, $56,352 $321,872, $228,000 2015 During the six June 30, 2016, 2015 3 1,528,571 $0.45 June 1, 2020. During the six June 30, 2016, $535,000, Warrants Issued C oncurrently with Line of Credit During the six June 30, 2016 300,000 $0.35 June 2021. The relative fair value of warrants issued resulted in $237,405 Exercise of Warrants During the six June 30, 2017, 510,000 $153,000 370,000 $0.30 140,000 $0.25 No six June 30, 2016. We have certain warrants outstanding to purchase our common stock, at various prices, as summarized in the following tables: Balance, June 30, 2016 Number of Shares Price Range Outstanding as of December 31, 2015 13,779,438 $0.125 – 1.00 Issued 1,828,571 0.45 Expired (183,545 ) 0.55 Outstanding as of June 30, 2016 15,424,464 $0.125 – 1.00 Balance, June 30, 201 7 Number of Shares Price Range Outstanding as of December 31, 2016 20,035,114 $0.125 – 1.00 Issued 990,727 0.42 – 0.70 Exercised (510,000 ) 0.25 – 0.30 Expired — — Outstanding as of June 30, 2017 20,515,841 $0.125 – 1.00 The fair value of each award grant is estimated on the date of grant using the Black-Scholes option-pricing model. The determination of expense of warrants issued for services or settlement also uses the option-pricing model. The principal assumptions we used in applying this model were as follows for the six June 30: 2016 2017 Risk free interest rate 1.26 – 1.36% 1.83 – 1.93% Expected volatility 311 – 315% 293 – 297% Expected dividend yield — — Forfeiture rate — — Expected life in years 5 5 The risk-free interest rate is based on U.S Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock.

Note 6 - Accounts Payable and A

Note 6 - Accounts Payable and Accrued Expenses	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 6. Accounts payable and accrued expenses included the following: December 31, June 30 , 2016 2017 Accounts payable and accrued expenses $ 22,231 $ 158,690 Payroll tax liability 137,500 137,500 Accrued officer bonus 80,000 — Accrued interest 40,372 48,248 Total accounts payable and accrued expenses $ 280,103 $ 344,438 The payroll tax liability is the Company’s estimate of payroll taxes due on the past services of independent contractors. The Company is currently attempting to reduce the liability to approximately $5,000 On September 27, 2016, $60,000 $20,000 2016. $40,000 January 2017. During the six June 30, 2016 2017, 746,943 1,807,829 $275,232 $168,022, During the six June 30, 2016 2017 546,157 683,875 $213,875 $337,246,

Note 7 - Noncontrolling Interes

Note 7 - Noncontrolling Interest	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 7 . Noncontrolling Interest In May 2012, December 17, 2012, 7,500 December 17, 2012, 1,500 three one third three On December 30, 2015, 9,830 $750,000. 4 2 not 40% 54%, three As set forth in Clyra’s Amended and Restated Articles of Incorporation, Preferred Shares accrue an annual dividend of 8% five no 510 December 20, June 30, 2017 $90,000. Holders of Preferred Shares are entitled to preferential payments in the event of a liquidation, dissolution or winding up of the company, in an amount equal to any accrued and unpaid dividends. After such preference, any remaining assets are distributed pro-rata between holders of Clyra common stock and Preferred Shares as if the Preferred Shares had converted to Clyra common stock. Holders of Preferred Shares may one one In addition to the foregoing, Clyra entered into a consulting agreement with Beach House Consulting, LLC, through which Jack B. Strommen will be providing consulting services to the company. Mr. Strommen is the founder of Beach House Consulting, LLC. Mr. Strommen will be assisting the company in its sales and marketing activities once it has FDA Approval on a product, at which point the agreement provides that Mr. Strommen is to receive $23,438 four June 30, 2017, not From inception, Clyra has generated no three six June 30, 2017, $387,490 $524,572.

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 8. Calvert Employment Agreement On May 2, 2017, April 30, 2007. The Calvert Employment Agreement provides that Mr. Calvert will continue to serve as the President and Chief Executive Officer of the Company and receive base compensation equal to his current rate of pay of $288,603 $800 four may The Calvert Employment Agreement provides that Mr. Calvert will be granted an option (the “Option”) to purchase 3,731,322 $0.45 ten five not 1,500,000 $3,000,000 $3,000,000 12 The Calvert Employment Agreement has a term of five may 120 360 nolo contendre one one one one The Calvert Employment Agreement requires Mr. Calvert to keep certain information confidential, not

Note 9 - Subsequent Events

Note 9 - Subsequent Events	6 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	Note 9. Management has evaluated subsequent events through the date of the filing of this Quarterly Report and management noted the following for disclosure. One-Year Convertible Notes , mature July 18, 2018 On July 18, 2017, $250,000 $0.42 July 18, 2018 two $280,000. 3% 400,000 $0.65 July 18, 2023. may 2017 two may O ne-Year Convertible Note s , mature December 30, 2017 The promissory notes issued on December 30, 2016 $0.57 July 18, 2017, December 30, 2016 $0.42 two December 30, 2016, $0.42 On July 20, 2017, $280,000 686,667 Two-Year Convertible Note On July 20, 2017, $400,000 10% $440,000, two 12% $0.42 2,000 $0.42 may Clyra Medical Technologies, Inc. On August 4, 2017, $160 $1,000,000 6,250 two $250,000 1,562.5 On July 22, 2017, $250,000 $270,400. 1,690 $160 Subsequent to the issuance of shares to investors in the offering and to Sanatio, BioLargo owns 15,298 46.33% two three Summer 2017 Subsequent to June 30, 2017, 2017 3 $182,200 five June 20, 2020. 433,810

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based compensation and financing transactions, uncollectible accounts receivable, asset impairment and amortization, and taxes, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-based Payments All share-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values. For stock issued to consultants and other non-employees for services, we record the expense based on the fair market value of the securities as of the date of the stock issuance. The issuance of fully vested stock warrants or options to non-employees are valued at the time of issuance utilizing the Black Scholes calculation and the amount is charged to expense. The issuance of stock warrants or options to non-employees that vest over time are revalued each reporting period until vested to determine the amount to be recorded as an expense in the respective period. As the warrants or options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the then current value on the date of vesting.
Warrant Policy [Policy Text Block]	Warrants The Unit Offerings of our convertible promissory note and a Series A stock purchase warrant are accounted for under the fair value and relative fair value method. The warrant is first not. If the warrant is determined to not The convertible note is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) which the effective convertible price of the note is less than the closing stock price on date of issuance. The adjusted BCF value is accounted for as equity. The warrant and BCF fair values are also recorded as a discount to the convertible promissory notes. The equity features of the convertible promissory notes resulted in a discount to the convertible notes that is equal to the proceeds received.
Non Cash Transactions [Policy Text Block]	Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company has designated the functional currency of Biolargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. We also may one
Government Grants [Policy Text Block]	Government Grants We have been awarded grants from the Canadian National Research Institute – Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC). The government grants received are considered other income and are included in our consolidated statements of operations. We received our first 2015 thirty $1,100,000. third six eighteen not The grants provide for (i) recurring monthly amounts and (ii) reimbursement of costs for research talent for which we invoice to request payment and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three six June 30, 2016 2017,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk All highly liquid investments with original maturities of three one June 30, 2017 December 31, 2016, $250,000 not June 30, 2017 December 31, 2016, $183,539 $1,660,153,
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for uncollectible receivables Management evaluates credit quality by evaluating the exposure to individual counterparties, and, where warranted, management also considers the credit rating or financial position, operating results and/or payment history of the counterparty. Management establishes an allowance for amounts for which collection is considered doubtful. Adjustments to previous assessments are recognized in income in the period in which they are determined. At June 30, 2017, $15,000.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In April 2016, 2016 10, 606 2014 09, 606 December 15, 2017. not In March 2016, No. 2016 09, two December 15, 2017. In February 2016, No. 2016 02, 12 December 15, 2018, not

Note 3 - Convertible Notes Pa17

Note 3 - Convertible Notes Payable and Lines of Credit (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Debt [Table Text Block]	DECEMBER 31, 201 6 JUNE 3 0 , 201 7 Current liabilities: Line of credit, matures December 1, 2017 $ 50,000 $ 50,000 Convertible notes payable One-Year Convertible notes, mature July 8, 2017 $ 280,000 $ — One-Year Convertible notes, mature December 30, 2017 280,000 280,000 Convertible notes, mature June 1, 2018* — 4,550,097 Total convertible notes payable $ 560,000 $ 4,830,097 Long-term liabilities: Clyra Line of credit, matures March 31, 2019 $ — $ 250,000 Convertible notes payable, net of current portion Convertible notes, mature June 1, 2018* $ 4,800,097 $ — Convertible notes, mature September 17, 2019 283,571 283,571 Convertible notes, mature December 31, 2019 167,000 292,000 Convertible notes, mature June 20, 2020 — 100,000 Total convertible notes payable , net of current portion $ 5,250,668 $ 675,571 Total $ 5,860,668 $ 5,805,668
Convertible Debt [Table Text Block]	Unit/ Conversion Price Warrant Exercise Price Aggregate $ 0.25 $ 0.40 $ 1,652,384 $ 0.35 $ 0.45 1,751,046 $ 0.55 $ 0.70 1,146,667 $ 4,550,097

Note 4 - Share-based Compensa18

Note 4 - Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Balance, June 30, 2016: Average Options Shares Exercise Price per Outstanding Available Price per share share Balances as of December 31, 2015 10,241,086 1,758,914 $0.23 – 1.89 $ 0.44 Granted 40,000 (40,000 ) 0.45 0.45 Expired — — — — Balance, June 30, 2016 10,281,086 1,718,914 $0.23 – 1.89 $ 0.44 Weighted Average Balance, June 30, 2017: Options Shares Exercise Price per Outstanding Available Price per share share Balances as of December 31, 2016 9,916,586 1,981,414 $0.23 – 1.89 $ 0.44 Granted 340,000 (340,000 ) 0.39 – 0.69 0.65 Exercised — — — — Balance, June 30, 2017 10,256,586 1,641,414 $0.23 – 1.89 $ 0.44
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2016 2017 Non Plan 2007 Plan Non Plan 2007 Plan Risk free interest rate 1.77 – 1.91% 1.26 – 1.36% 2.29 – 2.40% 2.31 – 2.40% Expected volatility 641 – 645% 311 – 315% 578 – 601% 578 – 601% Expected dividend yield — — — — Forfeiture rate — — — — Expected life in years 7 5 7 7
Outside of 2007 Plan [Member]
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Balance, June 30, 2016: Average Options Exercise Price per Outstanding Price per share share Balance, December 31, 2015 19,394,975 $0.18 – 1.00 $ 0.40 Granted 484,077 0.33 – 0.45 0.38 Exercised (60,000 ) 0.25 0.25 Balance, June 30, 2016 19,819,052 $0.18 – 1.00 $ 0.41 Weighted Average Balance, June 30, 2017: Options Exercise Price per Outstanding Price per share share Balance, December 31, 2016 20,148,766 $0.18 – 1.00 $ 0.43 Granted 4,552,201 0.43 – 0.67 $ 0.47 Expired (3,866,629 ) 0.18 0.18 Exercised (3,866,630 ) 0.18 0.18 Balance, June 30, 2017 16,967,708 $0.18 – 1.00 $ 0.41

Note 5 - Warrants (Tables)

Note 5 - Warrants (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Balance, June 30, 2016 Number of Shares Price Range Outstanding as of December 31, 2015 13,779,438 $0.125 – 1.00 Issued 1,828,571 0.45 Expired (183,545 ) 0.55 Outstanding as of June 30, 2016 15,424,464 $0.125 – 1.00 Balance, June 30, 201 7 Number of Shares Price Range Outstanding as of December 31, 2016 20,035,114 $0.125 – 1.00 Issued 990,727 0.42 – 0.70 Exercised (510,000 ) 0.25 – 0.30 Expired — — Outstanding as of June 30, 2017 20,515,841 $0.125 – 1.00
Schedule Of Assumptions Used To Determine Fair Value Of Warrants [Table Text Block]	2016 2017 Risk free interest rate 1.26 – 1.36% 1.83 – 1.93% Expected volatility 311 – 315% 293 – 297% Expected dividend yield — — Forfeiture rate — — Expected life in years 5 5

Note 6 - Accounts Payable and20

Note 6 - Accounts Payable and Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	December 31, June 30 , 2016 2017 Accounts payable and accrued expenses $ 22,231 $ 158,690 Payroll tax liability 137,500 137,500 Accrued officer bonus 80,000 — Accrued interest 40,372 48,248 Total accounts payable and accrued expenses $ 280,103 $ 344,438

Note 1 - Business and Organiz21

Note 1 - Business and Organization (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Aug. 14, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest		$ (2,517,794)	$ (1,668,335)	$ (4,577,870)	$ (3,312,728)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations				(2,048,628)	(1,693,661)
Working Capital		(3,175,349)		(3,175,349)
Assets, Current		561,346		561,346		$ 2,016,682
Retained Earnings (Accumulated Deficit)		(96,256,129)		(96,256,129)		(91,915,426)
Cash and Cash Equivalents, at Carrying Value		433,539	$ 889,029	433,539	889,029	$ 1,910,153	$ 1,763,114
Cash and Cash Equivalents, Period Increase (Decrease)				(1,476,614)	$ (874,085)
Long-term Debt, Gross		5,805,668		5,805,668
Convertible Debt		4,830,097		4,830,097
Accounts Payable and Accrued Liabilities		$ 344,438		$ 344,438
Subsequent Event [Member]
Proceeds from Issuance of Private Placement	$ 800,000

Note 2 - Summary of Significa22

Note 2 - Summary of Significant Accounting Policies (Details Textual)	6 Months Ended
	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)
Cash, Uninsured Amount	$ 183,539	$ 1,660,153
Allowance for Doubtful Accounts, Premiums and Other Receivables	$ 15,000
Canadian Government Grants [Member]
Number of Grants Received	30
Grants Receivable	$ 1,100,000
Canadian Government Grants [Member] | Minimum [Member]
Grant Term	180 days
Canadian Government Grants [Member] | Maximum [Member]
Grant Term	1 year 180 days

Note 3 - Convertible Notes Pa23

Note 3 - Convertible Notes Payable and Lines of Credit (Details Textual) - USD ($)

May 24, 2017

Jan. 13, 2017

Dec. 30, 2016

Dec. 27, 2016

Sep. 17, 2016

Jul. 08, 2016

Jun. 06, 2016

May 15, 2017

Jun. 30, 2017

Mar. 31, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Dec. 31, 2016

Share Price

$ 0.83

$ 0.86

$ 0.70

Interest Expense, Debt

$ 1,119,273

$ 478,525

$ 2,072,829

$ 884,850

Proceeds from Lines of Credit

$ 300,000

Line of Credit Facility, Interest Rate During Period

18.00%

Debt Conversion, Original Debt, Amount

243,824

183,159

Line of Credit, Current

$ 50,000

$ 50,000

$ 50,000

Winter 2016 Unit Offering [Member]

Class of Warrant or Right, Exercise Period

30 days

Class of Warrant or Right, Exercise Period Condition, Number of Trading Days Common Stock Closes at or above 2 Times the Exercise Price

10 days

Proceeds from Issuance of Units

$ 292,000

Units Issued During Period, Value, New Issues

$ 600,000

Debt Instrument, Convertible, Conversion Price

$ 0.57

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

512,281

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.70

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Number of Trading Days Prior to Interest Payment Due Date if Paid by Issuance of Common Stock

20 days

Debt Conversion before Maturity, Number of Trading Days Common Stock Closes at or above 3 Times the Unit Price

10 days

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

Winter 2016 Unit Offering [Member] | Three accredited Investors [Member]

Proceeds from Issuance of Units

$ 125,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

219,298

Clyra Medical Technology Inc [Member] | Sanatio [Member]

Line of Credit Facility, Maximum Borrowing Capacity

$ 250,000

Original Issue Discount, Percentage

5.00%

Proceeds from Lines of Credit

$ 75,000

$ 175,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Clyra Medical Technology Inc [Member]

Subsidiary, Parent Ownership Interest

54.00%

The 2015 Unit Offering [Member]

Debt Instrument, Convertible, Conversion Price

Class of Warrant or Right, Exercise Price of Warrants or Rights

Proceeds from Convertible Debt

$ 535,000

Debt Instrument, Interest Rate, Stated Percentage

12.00%

12.00%

Warrants Issued Concurrently With One Year Convertible Note [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

400,000

400,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.42

$ 0.75

$ 0.65

Class of Warrant or Right, Expiration Term

5 years

5 years

Warrant Issued in Exchange of Cancelled Line of Credit [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

515,583

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.70

Warrants Issued Concurrently to the Summer 2017 Unit Offering [Member]

Class of Warrant or Right, Exercise Period

30 days

Class of Warrant or Right, Exercise Period Condition, Number of Trading Days Common Stock Closes at or above 2 Times the Exercise Price

10 days

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.65

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

One Year Convertible Notes [Member]

Debt Instrument, Convertible, Conversion Price

$ 0.57

$ 0.45

$ 0.57

Debt Conversion, Original Debt, Amount

$ 280,000

Debt Conversion, Converted Instrument, Shares Issued

640,889

Proceeds from Convertible Debt

$ 250,000

$ 250,000

Debt Instrument, Face Amount

$ 280,000

$ 280,000

Debt Instrument, Interest Rate, Stated Percentage

3.00%

3.00%

Summer 2017 Unit Offering [Member]

Proceeds from Issuance of Private Placement

$ 1,500,000

Debt Instrument, Convertible, Conversion Price

$ 0.42

Debt Instrument, Interest Rate, Stated Percentage

12.00%

Number of Trading Days Prior to Interest Payment Due Date if Paid by Issuance of Common Stock

20 days

Debt Conversion before Maturity, Number of Trading Days Common Stock Closes at or above 3 Times the Unit Price

10 days

Conversion of Line of Credit to 2015 Unit Offering [Member]

Debt Conversion, Original Debt, Accrued Interest Amount

$ 33,571

Debt Instrument, Convertible, Conversion Price

$ 0.55

Debt Conversion, Original Debt, Amount

$ 250,000

Promissory Notes Issued in 2015 Unit Offering and Accrued Interest Into Common Stock [Member]

Debt Conversion, Original Debt, Amount

$ 250,000

Debt Conversion, Converted Instrument, Shares Issued

406,789

Line of Credit [Member]

Debt Instrument, Term

270 days

Note 3 - Convertible Notes Pa24

Note 3 - Convertible Notes Payable and Lines of Credit - Schedule of Debt (Details) - USD ($)		Jun. 30, 2017	Dec. 31, 2016
Line of credit		$ 4,830,097	$ 560,000
Convertible notes		675,571	5,250,668
Total		5,805,668	5,860,668
Line of Credit, Matures December 1, 2017 [Member]
Line of credit		50,000	50,000
Convertible Notes Maturing on July 8, 2017 [Member]
Line of credit			280,000
Convertible Notes Maturing on December 30, 2017 [Member]
Line of credit		280,000	280,000
Convertible Notes Maturing on June 1, 2018 [Member]
Line of credit		4,550,097
Convertible notes	[1]		4,800,097
Line of Credit, Maturing on March 31, 2019 [Member]
Convertible notes		250,000
Convertible Notes Maturing on September 17, 2019 [Member]
Convertible notes		283,571	283,571
Convertible Notes Maturing on December 31, 2019 [Member]
Convertible notes		292,000	167,000
Convertible Notes, Maturing on June 20, 2020 [Member]
Convertible notes		$ 100,000
[1]	The convertible notes that mature June 1, 2018, were considered "long-term" liabilities as of December 31, 2016, and "current" liabilities (due within one year) as of June 30, 2017. As such, those same liabilities are in both the "long-term" and "current" liabilities section in the above table.

Note 3 - Convertible Notes Pa25

Note 3 - Convertible Notes Payable and Lines of Credit - Pricing Supplements (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Aggregate outstanding	$ 675,571	$ 5,250,668
The 2015 Unit Offering [Member]
Warrant exercise price (in dollars per share)
Aggregate outstanding	$ 4,550,097
Conversion price (in dollars per share)
Pricing Supplement No.1 [Member] | The 2015 Unit Offering [Member]
Warrant exercise price (in dollars per share)	$ 0.40
Aggregate outstanding	$ 1,652,384
Conversion price (in dollars per share)	$ 0.25
Pricing Supplement No.2 [Member] | The 2015 Unit Offering [Member]
Warrant exercise price (in dollars per share)	$ 0.45
Aggregate outstanding	$ 1,751,046
Conversion price (in dollars per share)	$ 0.35
Pricing Supplement No.3 [Member] | The 2015 Unit Offering [Member]
Warrant exercise price (in dollars per share)	$ 0.70
Aggregate outstanding	$ 1,146,667
Conversion price (in dollars per share)	$ 0.55

Note 4 - Share-based Compensa26

Note 4 - Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, xbrli-pure in Thousands	Jun. 19, 2017	May 02, 2017	Apr. 30, 2017	Feb. 10, 2017	Jun. 20, 2016	Mar. 21, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 30, 2016	Dec. 27, 2016	Sep. 17, 2016
Share Price											$ 0.83	$ 0.86	$ 0.70
Employee Stock Option [Member]
Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate									0.00%
The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.65	$ 0.45
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									340,000	40,000
Outside of the 2007 Plan [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.47	$ 0.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									4,552,201	484,077
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value							$ 20,025	$ 75,405	$ 40,050	$ 170,310
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period									3,866,629
Selling, General and Administrative Expenses [Member]
Allocated Share-based Compensation Expense							235,671	$ 189,601	$ 515,959	$ 491,440
Selling, General and Administrative Expenses [Member] | The 2007 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense						$ 119,971
President and Chief Executive Officer [Member]
Employment Agreement, Common Stock, Expect to Grant, Subject to Lock-Up Agreement		1,500,000
Employment Agreement, Option, Number of Shares, Expected to Grant		3,731,322
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Employment Agreement, Term		5 years
Employment Agreement, Lock-up Agreement, Successful Commercialization, Minimum Cash Receipt		$ 3,000,000
Employment Agreement, Lock-up Agreement, Minimum Revenue Recognized		$ 3,000,000
President and Chief Executive Officer [Member] | Non-Qualified Stock Option [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0.45
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted in Period, Fair Value		$ 1,679,095
President and Chief Executive Officer [Member] | 2007 Stock Option [Member]
Investment Options, Exercise Price			$ 0.18
Stock Issued During Period, Shares, New Issues			3,866,630
Share Price			$ 0.51
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period			3,866,629
President and Chief Executive Officer [Member] | Shares Issued for the Exercise of 2007 Stock Option [Member]
Stock Issued During Period, Shares, New Issues			2,501,937
President and Chief Executive Officer [Member] | Selling, General and Administrative Expenses [Member] | Non-Qualified Stock Option [Member]
Allocated Share-based Compensation Expense							27,985
Non-employee Members of the Board of Directors [Member] | The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.43				$ 0.45
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	40,000				40,000
Non-employee Members of the Board of Directors [Member] | Selling, General and Administrative Expenses [Member] | The 2007 Equity Incentive Plan [Member]
Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted in Period, Fair Value					$ 18,000
Allocated Share-based Compensation Expense	$ 15,600
Chief Financial Officer [Member] | The 2007 Equity Incentive Plan [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 0.69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares				125,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Remaining Number of Shares to Vest Each Month				25,000
Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted in Period, Fair Value							207,000		207,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				300,000
Chief Financial Officer [Member] | Selling, General and Administrative Expenses [Member] | The 2007 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense							$ 51,750		$ 155,250
Board of Directors and Vendors [Member] | The 2007 Equity Incentive Plan [Member]
Sharebased Compensation Arrangement By Sharebased Payment Award Options Expiration Period Extension						5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						307,777
Board of Directors and Vendors [Member] | Outside of the 2007 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							237,353	220,554	820,879	484,077
Board of Directors and Vendors [Member] | Outside of the 2007 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.43	$ 0.33
Board of Directors and Vendors [Member] | Outside of the 2007 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.67	$ 0.45
Board of Directors and Vendors [Member] | Selling, General and Administrative Expenses [Member] | Outside of the 2007 Plan [Member]
Allocated Share-based Compensation Expense							$ 120,311	$ 96,196	$ 277,074	$ 183,159

Note 4 - Share-based Compensa27

Note 4 - Share-based Compensation - Stock Options Issued Under the 2007 Equity Incentive Plan (Details) - The 2007 Equity Incentive Plan [Member] - $ / shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Weighted average price per share, beginning balance (in dollars per share)	$ 0.44	$ 0.44
Weighted average price per share, ending balance (in dollars per share)	$ 0.44	$ 0.44
Options outstanding, beginning balance (in shares)	9,916,586	10,241,086
Shares available, beginning balance (in shares)	1,981,414	1,758,914
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	340,000	40,000
Shares available, granted (in shares)	(340,000)	(40,000)
Exercise price per share, granted (in dollars per share)		$ 0.45
Weighted average price per share, granted (in dollars per share)	$ 0.65	$ 0.45
Options outstanding, ending balance (in shares)	10,256,586	10,281,086
Shares available, ending balance (in shares)	1,641,414	1,718,914
Minimum [Member]
Exercise price per share, beginning balance (in dollars per share)	$ 0.23	$ 0.23
Exercise price per share, granted (in dollars per share)	0.39
Exercise price per share, ending balance (in dollars per share)	0.23	0.23
Maximum [Member]
Exercise price per share, beginning balance (in dollars per share)	1.89	1.89
Exercise price per share, granted (in dollars per share)	0.69
Exercise price per share, ending balance (in dollars per share)	$ 1.89	$ 1.89

Note 4 - Share-based Compensa28

Note 4 - Share-based Compensation - Stock Options Issued Outside of the 2007 Equity Incentive Plan (Details) - Outside of the 2007 Plan [Member] - $ / shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Weighted average price per share, ending balance (in dollars per share)	$ 0.41	$ 0.41
Options outstanding, beginning balance (in shares)	20,148,766	19,394,975
Weighted average price per share, beginning balance (in dollars per share)	$ 0.43	$ 0.40
Options outstanding, granted (in shares)	4,552,201	484,077
Weighted average price per share, granted (in dollars per share)	$ 0.47	$ 0.38
Options outstanding, exercised (in shares)	3,866,630	(60,000)
Options outstanding, expired (in shares)	(3,866,629)
Exercise price per share, expired (in dollars per share)	$ 0.18
Weighted average price per share, expired (in dollars per share)	$ 0.18
Exercise of stock options (in shares)	(3,866,630)	60,000
Exercised, exercise price per share (in dollars per share)	$ 0.18	$ 0.25
Weighted average price per share, exercised (in dollars per share)	$ 0.18	$ 0.25
Options outstanding, ending balance (in shares)	16,967,708	19,819,052
Minimum [Member]
Exercise price per share, beginning balance (in dollars per share)	$ 0.18	$ 0.18
Granted, exercise price per share (in dollars per share)	0.43	0.33
Exercised, exercise price per share (in dollars per share)
Exercise price per share, ending balance (in dollars per share)	0.18	0.18
Maximum [Member]
Exercise price per share, beginning balance (in dollars per share)	1	1
Granted, exercise price per share (in dollars per share)	0.67	0.45
Exercised, exercise price per share (in dollars per share)
Exercise price per share, ending balance (in dollars per share)	$ 1	$ 1

Note 4 - Share-based Compensa29

Note 4 - Share-based Compensation - Stock Options, Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Non Plan [Member]
Risk free interest rate, minimum	2.29%	1.77%
Risk free interest rate, maximum	2.40%	1.91%
Expected volatility, minimum	578.00%	641.00%
Expected volatility, maximum	601.00%	645.00%
Expected life in years (Year)	7 years	7 years
The 2007 Equity Incentive Plan [Member]
Risk free interest rate, minimum	2.31%	1.26%
Risk free interest rate, maximum	2.40%	1.36%
Expected volatility, minimum	578.00%	311.00%
Expected volatility, maximum	601.00%	315.00%
Expected life in years (Year)	7 years	5 years

Note 5 - Warrants (Details Text

Note 5 - Warrants (Details Textual) - USD ($)	May 24, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Jan. 13, 2017	Dec. 31, 2016	Dec. 30, 2016	Dec. 27, 2016	Sep. 17, 2016	Jul. 08, 2016	Dec. 31, 2015
Share Price									$ 0.83	$ 0.86	$ 0.70
Amortization of Debt Discount (Premium)				$ 1,723,396	$ 668,257
Derivative Liability, Current		$ 570,595		570,595				$ 663,560
Fair Value Adjustment of Warrants		$ (56,352)		$ (321,872)
Stock Issued During Period, Shares, Exercise of Warrants				510,000	0
Proceeds from Warrant Exercises				$ 153,000
Class of Warrant or Right, Issued During Period				990,727	1,828,571
Class of Warrant or Right, Outstanding		20,515,841	15,424,464	20,515,841	15,424,464			20,035,114					13,779,438
Summer 2017 Unit Offering [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.42
Warrants Issued Concurrently With One Year Convertible Note [Member]
Discount On Convertible Note Payable									$ 280,000			$ 160,000
Derivative Liability, Current		$ 570,595		$ 570,595
Fair Value Adjustment of Warrants		$ 56,352		321,872
Class of Warrant or Right, Interest Expense				$ 228,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									400,000			400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.42								$ 0.75			$ 0.65
Warrants Issued Concurrently to the Summer 2017 Unit Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.65
Class of Warrant or Right, Issued During Period	219,048
Class of Warrant or Right, Outstanding	619,048
Warrants Issued Concurrently to the Summer 2017 Unit Offering 2 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.42
Class of Warrant or Right, Issued During Period	314,285
Class of Warrant or Right, Outstanding	714,285
The 2015 Unit Offering [Member]
Discount On Convertible Note Payable			$ 535,000		$ 535,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,528,571		1,528,571
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.45		$ 0.45
Warrants Issued Concurrently with Line of Credit [Member]
Debt Instrument, Unamortized Discount			$ 237,405		$ 237,405
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			300,000		300,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.35		$ 0.35
Warrants With Exercise Price $0.30 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		370,000		370,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.30		$ 0.30
Warrants With Exercise Price $0.25 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		140,000		140,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.25		$ 0.25
Warrants Issued Concurrently to the Summer 2017 Unit Offering [Member]
Discount On Convertible Note Payable		$ 125,000		$ 125,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		238,096		238,096
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.65		$ 0.65
Warrants Issued Concurrently with Winter 2016 Unit Offering [Member]
Discount On Convertible Note Payable						$ 125,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						219,298	512,281
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.70	$ 0.70

Note 5 - Warrants - Warrants Ou

Note 5 - Warrants - Warrants Outstanding (Details) - $ / shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Issued (in shares)	990,727	1,828,571
Issued, price range (in dollars per share)		$ 0.45
Expired (in shares)	(510,000)	(183,545)
Beginning balance, outstanding (in shares)	20,035,114	13,779,438
Expired, price range (in dollars per share)		$ 0.55
Ending balance, outstanding (in shares)	20,515,841	15,424,464
Minimum [Member]
Issued, price range (in dollars per share)	$ 0.42
Beginning balance, outstanding, price range (in dollars per share)	0.25	$ 0.125
Beginning balance, outstanding, price range (in dollars per share)	0.125
Ending balance, outstanding, price range (in dollars per share)	0.125
Maximum [Member]
Issued, price range (in dollars per share)	0.70
Beginning balance, outstanding, price range (in dollars per share)	0.30	$ 1
Beginning balance, outstanding, price range (in dollars per share)	1
Ending balance, outstanding, price range (in dollars per share)	$ 1

Note 5 - Warrants - Assumptions

Note 5 - Warrants - Assumptions Used to Determine Fair Value of Warrants (Details)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Expected life in years (Year)	5 years	5 years
Minimum [Member]
Risk free interest rate	1.83%	1.26%
Expected volatility	293.00%	311.00%
Maximum [Member]
Risk free interest rate	1.93%	1.36%
Expected volatility	297.00%	315.00%

Note 6 - Accounts Payable and33

Note 6 - Accounts Payable and Accrued Expenses (Details Textual) - USD ($)	Sep. 27, 2016	Jan. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Accrued Payroll Taxes, Possible Reduced Amount			$ 5,000		$ 5,000
Accrued Bonuses, Current							$ 80,000
Selling, General and Administrative Expense			$ 1,162,018	$ 923,564	$ 2,217,073	$ 1,854,471
Stock Issued During Period, Shares, Issued to Settle Accrued Interest Liability					683,875	546,157
Interest Expense [Member]
Stock Issued During Period, Grant Date Fair Value, Issued to Settle Accrued Interest Liability					$ 337,246	$ 213,875
Chief Executive Officer [Member]
Accrued Bonuses, Current	$ 60,000
Bonuses Paid	$ 20,000	$ 40,000
Consultants [Member]
Stock Issued During Period, Shares, Issued for Services					1,807,829	746,943
Selling, General and Administrative Expense					$ 168,022	$ 275,232

Note 6 - Accounts Payable and34

Note 6 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accounts payable and accrued expenses	$ 158,690	$ 22,231
Payroll tax liability	137,500	137,500
Accrued officer bonus		80,000
Accrued interest	48,248	40,372
Total accounts payable and accrued expenses	$ 344,438	$ 280,103

Note 7 - Noncontrolling Inter35

Note 7 - Noncontrolling Interest (Details Textual) - USD ($)	Dec. 30, 2015	Dec. 17, 2012	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Consulting Services, Monthly Payment	$ 23,438
Consulting Services, Period of Services	4 years
Net Income (Loss) Attributable to Noncontrolling Interest			$ (173,911)	$ (54,859)	$ (237,167)	$ (121,831)
Revenue, Net			99,978	$ 38,986	145,995	$ 52,928
Clyra Medical Technology Inc [Member]
Sale of Stock, Percentage of Ownership after Transaction	54.00%
Clyra Medical Technology Inc [Member]
Investment Owned, Balance, Shares		7,500
Preferred Stock, Dividend Rate, Percentage	8.00%
Preferred Shares Dividend, Period	5 years
Dividends Payable			90,000		90,000
Net Income (Loss) Attributable to Noncontrolling Interest			(387,490)		(524,572)
Revenue, Net			$ 0		$ 0
Clyra Medical Technology Inc [Member] | Series A Preferred Stock [Member] | Sanatio [Member]
Sale of Stock, Number of Shares Issued in Transaction	9,830
Proceeds from Issuance or Sale of Equity	$ 750,000
Clyra Medical Technology Inc [Member] | Each of 3 Individuals [Member]
Stock Issued During Period, Shares, New Issues		1,500
Sanatio [Member] | Clyra Medical Technology Inc [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	40.00%

Note 8 - Commitments and Cont36

Note 8 - Commitments and Contingencies (Details Textual) - President and Chief Executive Officer [Member]	May 02, 2017USD ($)$ / sharesshares
Employment Agreement, Annual Base Compensation	$ 288,603
Employment Agreement, Car Allowance Monthly	$ 800
Employment Agreement, Option, Number of Shares, Expected to Grant | shares	3,731,322
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Employment Agreement, Common Stock, Expect to Grant, Subject to Lock-Up Agreement | shares	1,500,000
Employment Agreement, Lock-up Agreement, Successful Commercialization, Minimum Cash Receipt	$ 3,000,000
Employment Agreement, Lock-up Agreement, Minimum Revenue Recognized	$ 3,000,000
Employment Agreement, Term	5 years
Non-Qualified Stock Option [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 0.45
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years

Note 9 - Subsequent Events (Det

Note 9 - Subsequent Events (Details Textual)	Aug. 04, 2017USD ($)$ / sharesshares	Jul. 22, 2017USD ($)$ / sharesshares	Jul. 20, 2017USD ($)$ / shares	Jul. 18, 2017USD ($)$ / sharesshares	Dec. 30, 2016USD ($)$ / shares	Jul. 08, 2016USD ($)$ / shares	Aug. 14, 2017USD ($)shares	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2016$ / shares
Debt Conversion, Converted Instrument, Amount								$ 530,000
Subsequent Event [Member]
Proceeds from Convertible Debt							$ 182,200
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares							433,810
Proceeds from Issuance of Private Placement							$ 800,000
Subsequent Event [Member] | Clyra Medical Technology Inc [Member]
Noncontrolling Interest, Increase from Subsidiary Equity Issuance	$ 250,000
Stock Issued During Period, Shares, New Issues | shares	1,562.5
Subsequent Event [Member] | Clyra [Member]
Noncontrolling Interest, Ownership Percentage by Parent							46.33%
Common Stock, Shares Owned | shares							15,298
Subsequent Event [Member] | Clyra Medical Technology Inc [Member]
Proceeds from Issuance of Private Placement	$ 1,000,000
Stock Issued During Period, Shares, New Issues | shares	6,250
Shares Issued, Price Per Share | $ / shares	$ 160
Subsequent Event [Member] | Sanatio [Member]
Debt Conversion, Converted Instrument, Amount		$ 250,000
Long-term Line of Credit		$ 270,400
Stock Issued During Period, Shares, New Issues | shares		1,690
Shares Issued, Price Per Share | $ / shares		$ 160
One Year Convertible Notes [Member]
Proceeds from Convertible Debt					$ 250,000	$ 250,000
Debt Instrument, Face Amount					$ 280,000	$ 280,000
Debt Instrument, Interest Rate, Stated Percentage					3.00%	3.00%
Debt Instrument, Convertible, Conversion Price | $ / shares					$ 0.57	$ 0.45				$ 0.57
One Year Convertible Notes [Member] | Subsequent Event [Member]
Proceeds from Convertible Debt				$ 250,000
Debt Instrument, Face Amount				$ 280,000
Debt Instrument, Interest Rate, Stated Percentage				3.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				400,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 0.65
Debt Instrument, Convertible, Conversion Price | $ / shares				$ 0.42
Debt Instrument, Convertible, Number of Equity Instruments				686,667
Two Year Convertible Note [Member] | Subsequent Event [Member]
Proceeds from Convertible Debt			$ 400,000
Debt Instrument, Discount Percent			10.00%
Debt Instrument, Face Amount			$ 440,000
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Debt Instrument, Convertible, Conversion Price | $ / shares			$ 0.42
Debt Instrument, Convertible, Number of Equity Instruments			2,000